How would COVID-19 vaccine makers adapt to variants?
COVID-19 vaccines appear to be working against today’s variants, but companies are making plans to update their shots if needed
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.How would COVID-19 vaccine makers adapt to variants?
By tweaking their vaccines, a process that should be easier than coming up with the original shots.
Viruses constantly mutate as they spread, and most changes aren't significant. First-generation COVID-19 vaccines appear to be working against today's variants, but makers already are taking steps to update their recipes if health authorities decide that's needed.
COVID-19 vaccines by Pfizer and Moderna are made with new technology that's easy to update. The so-called mRNA vaccines use a piece of genetic code for the spike protein that coats the coronavirus, so your immune system can learn to recognize and fight the real thing.
If a variant with a mutated spike protein crops up that the original vaccine can't recognize, companies would swap out that piece of genetic code for a better match — if and when regulators decide that's necessary.
Updating other COVID-19 vaccines could be more complex. The AstraZeneca vaccine, for example, uses a harmless version of a cold virus to carry that spike protein gene into the body. An update would require growing cold viruses with the updated spike gene.
The Food and Drug Administration said studies of updated COVID-19 vaccines won’t have to be as large or long as for the first generation of shots. Instead, a few hundred volunteers could receive experimental doses of a revamped vaccine and have their blood checked for signs it revved up the immune system as well as the original vaccines.
More difficult is deciding if the virus has morphed enough to modify shots.
Globally, health authorities will monitor coronavirus mutations to spot vaccine-resistant mutations. They'd also have to decide whether any revamped vaccine should protect against more than one variant.
Overall the process would be similar to what already happens with flu vaccine. Influenza viruses mutate much faster than coronaviruses, so flu shots are adjusted every year and must protect against multiple strains.
___
The AP is answering your questions about the coronavirus in this series. Submit them at: FactCheck@AP.org.
Read previous Viral Questions:
How do we know the COVID-19 vaccines are safe?
Can I take painkillers before or after a COVID-19 vaccine?
What should I know about COVID-19 vaccines if I’m pregnant?